{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:14:33Z","timestamp":1790806473866,"version":"4.1.0"},"reference-count":102,"publisher":"Informa UK Limited","issue":"3","funder":[{"name":"BMS, Celgene, Janssen, GSK, Karyopharm, Amgen, Oncopeptides and Prothena"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.2217\/fon-2021-1090","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T15:30:09Z","timestamp":1638459009000},"page":"277-289","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":58,"title":["Idecabtagene Vicleucel (ide-cel) CAR T-cell Therapy for Relapsed and Refractory Multiple Myeloma"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-9595","authenticated-orcid":false,"given":"Larry D","family":"Anderson Jr","sequence":"first","affiliation":[{"name":"Myeloma,Waldenstrom\u2019s & Amyloidosis Program,Simmons Comprehensive Cancer Center,UT Southwestern Medical Center,\rDallas,\rTX 75390-8565,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"issue":"2","key":"e_1_3_2_3_1","first-page":"135","article-title":"The American Cancer Society\u2019s facts & figures: 2020 edition","volume":"11","author":"Viale PH","year":"2020","unstructured":"Viale PH . The American Cancer Society\u2019s facts & figures: 2020 edition. J. Adv. Pract. Oncol.11(2), 135\u2013136 (2020).","journal-title":"J. Adv. Pract. Oncol."},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25791"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26010"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02259"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30576-X"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-711903"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126397"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0427-6"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S138765"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(87)90502-X"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4597"},{"issue":"8","key":"e_1_3_2_22_1","first-page":"878","article-title":"Axicabtagene ciloleucel: the first FDA-spproved CAR T-cell therapy for relapsed\/refractory large B-cell lymphoma","volume":"10","author":"King AC","year":"2019","unstructured":"King AC , OrozcoJS. Axicabtagene ciloleucel: the first FDA-spproved CAR T-cell therapy for relapsed\/refractory large B-cell lymphoma. J. Adv. Pract. Oncol.10(8), 878\u2013882 (2019).","journal-title":"J. Adv. Pract. Oncol."},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-018-0470-x"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0451-2"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2010.59"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocit.2014.11.001"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI86000"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8084"},{"key":"e_1_3_2_31_1","article-title":"A phase I study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma","author":"Wang D","year":"2021","unstructured":"Wang D , WangJ, HuGet al. A phase I study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed\/refractory multiple myeloma. Blood 137(21), 2890-2901 (2021).","journal-title":"Blood"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0681-6"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000050"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.8005"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139802"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4463"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2422"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01821"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2043"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031330"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-017-0538-x"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00962-7"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI18025"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1641196"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1290\/0508054.1"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2006.11.002"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0548"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403302"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0102-70"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46110"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2019.08.002"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.001"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.8007"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2016.12.006"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004749"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf8621"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1209"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.5.2591"},{"issue":"1","key":"e_1_3_2_59_1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-134324","article-title":"Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma: updated results from phase 1 CRB-401 study","volume":"136","author":"Lin Y","year":"2020","unstructured":"Lin Y , RajeNS, BerdejaJGet al. Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma: updated results from phase 1 CRB-401 study. Blood136(Suppl. 1), 26\u201327 (2020).","journal-title":"Blood"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.8016"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9103120"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2224"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3503"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21177-5"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0184-6"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0146-z"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000466"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2016.11"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.756"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv439"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000035"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0291"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0041-7"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01616"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01134-4"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.11.002"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz017"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.21037\/sci-2020-029"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002228"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.022"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.8036"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0487-3"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190902856824"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26914"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100596"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI84813"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.08.003"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136665"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8525"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000722"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30734-0"},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1858790"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0907"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS8053"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-140410"},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129405"},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"e_1_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-140641"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2021-1090","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:43:16Z","timestamp":1719124996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2021-1090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":102,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.2217\/fon-2021-1090"],"URL":"https:\/\/doi.org\/10.2217\/fon-2021-1090","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-08-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}